PCM
FATE icon

Pinz Capital Management’s Fate Therapeutics FATE Stock Holding History

Pinz Capital Management’s Portfolio FATE Stock Details FATE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-66,900
Closed -$2.29M – 140
2020
Q2 		$2.29M Buy
+66,900
New +$1.99M 1.05% 34

Other funds holding FATE

RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JJIJ
Johnson & Johnson Innovation - JJDC New Brunswick, New Jersey $978M AUM 102.17% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Pinz Capital Management's FATE Position: Q3 2020 in Review

Pinz Capital Management sold out of Fate Therapeutics (FATE) in Q3 2020, closing a stake of 66,900 shares — an estimated $2.29M sold.

Pinz Capital Management first reported a position in FATE in Q2 2020 and held it in 1 quarter. The position peaked at $2.29M in Q2 2020. 211 funds tracked by Wall St. Rank hold FATE as of Q3 2020.

  • Pinz Capital Management reported no remaining Fate Therapeutics position as of Q3 2020 after selling out during the quarter.
  • Pinz Capital Management sold 66,900 Fate Therapeutics shares in Q3 2020, an estimated $2.29M.
  • Pinz Capital Management first reported a position in Fate Therapeutics in Q2 2020 and held it in 1 quarter.
  • Pinz Capital Management's Fate Therapeutics position peaked at $2.29M in Q2 2020.
  • 211 funds tracked by Wall St. Rank held Fate Therapeutics as of Q3 2020.

Based on Pinz Capital Management's 13F filing for Q3 2020, filed 16 Nov 2020.